BNTC · Benitec Biopharma Inc. · Documents

Nov 10

Quarterly report 10-Q FY2023 Q1, ended Sep 30

Quarterly report for FY2023 Q1

Revenue $0 Net loss $5.09M Diluted EPS -$0.47

Oct 25

Proxy statement DEF 14A Meeting Dec 7, 2022

Proxy statement

Oct 25

Proxy statement DEFA14A

Proxy statement

Oct 18

Current report 8-K Events of Oct 12

Director or officer change, or executive pay

Oct 14

Proxy statement PRE 14A

Proxy statement

Sep 16

Current report 8-K Events of Sep 12

Entered into a material agreement, Other events

Sep 12

Registration statement S-1/A

Registration statement

Sep 9

Registration statement S-1/A

Registration statement

Sep 7

Current report 8-K Events of Sep 6

Delisting notice or listing transfer

Sep 2

Current report 8-K

Financial results

Sep 2

Annual report 10-K FY2022, ended Jun 30

Annual report for FY2022

Revenue $73K ▲ 23.7% Net loss $18.21M Diluted EPS -$2.23

Aug 10

Registration statement S-1/A

Registration statement

Aug 8

Registration statement S-1/A

Registration statement

Jul 29

Registration statement S-1

Registration statement

May 16

Current report 8-K

Financial results

May 16

Quarterly report 10-Q FY2022 Q3, ended Mar 31

Quarterly report for FY2022 Q3

Revenue $48K ▲ 4700.0% Net loss $3.28M

Feb 14

Current report 8-K

Financial results

Feb 14

Quarterly report 10-Q FY2022 Q2, ended Dec 31

Quarterly report for FY2022 Q2

Revenue $25K ▲ 2400.0% Net loss $4.82M

Jan 21

Current report 8-K/A Events of Dec 8

Shareholder vote results

Dec 21

Current report 8-K Events of Dec 17

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Dec 13

Current report 8-K Events of Dec 8

Director or officer change, or executive pay, Shareholder vote results

Nov 15

Current report 8-K

Financial results

Nov 15

Quarterly report 10-Q FY2022 Q1, ended Sep 30

Quarterly report for FY2022 Q1

Revenue $0 Net loss $5.05M

Oct 22

Proxy statement DEF 14A Meeting Dec 8, 2021

Proxy statement

Oct 12

Proxy statement PRE 14A

Proxy statement

Sep 20

Current report 8-K

Financial results

Sep 20

Current report 8-K Events of Sep 15

Director or officer change, or executive pay

Sep 20

Annual report 10-K FY2021, ended Jun 30

Annual report for FY2021

Revenue $59K ▼ 42.2% Net loss $13.88M

May 12

Quarterly report 10-Q FY2021 Q3, ended Mar 31

Quarterly report for FY2021 Q3

Revenue $1000 ▼ 96.4% Net loss $3.91M

Apr 29

Current report 8-K Events of Apr 27

Entered into a material agreement, Other events

Feb 24

Current report 8-K

Regulation FD disclosure, Other events

Feb 18

Registration statement S-3

Registration statement

Feb 9

Quarterly report 10-Q FY2021 Q2, ended Dec 31

Quarterly report for FY2021 Q2

Revenue $1000 ▼ 98.7% Net loss $3.25M

Dec 15

Current report 8-K Events of Dec 9

Director or officer change, or executive pay

Dec 14

Current report 8-K Events of Dec 9

Director or officer change, or executive pay, Shareholder vote results

Nov 13

Quarterly report 10-Q FY2021 Q1, ended Sep 30

Quarterly report for FY2021 Q1

Revenue $55K ▲ 66.7% Net loss $2.72M

Nov 3

Current report 8-K Events of Nov 1

Change of auditor

Oct 27

Current report 8-K Events of Oct 22

Director or officer change, or executive pay

Oct 22

Proxy statement DEF 14A Meeting Dec 9, 2020

Proxy statement

Oct 6

Current report 8-K Events of Oct 2

Entered into a material agreement, Other events

Oct 1

Registration statement S-1/A

Registration statement

Sep 23

Current report 8-K

Financial results

Sep 23

Annual report 10-K FY2020, ended Jun 30

Annual report for FY2020

Revenue $102K ▼ 99.2% Net loss $8.27M

Aug 19

Current report 8-K/A Events of Jun 5

Change of auditor

Aug 18

Current report 8-K Events of Aug 14

Other events

Aug 14

Registration statement S-1

Registration statement

Jun 5

Current report 8-K

Change of auditor